Clinical Trial Update: A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 trial in diabetic patients to assess CE-326,597 for improving glucose control and reducing body weight.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• CE-326,597 (CE-326,597)

Snippet

Sponsor: Pfizer | Conditions: Weight Management, Treatment Of Obesity | Phase 2 | Status: COMPLETED